So Jacqueline, Tam Lai-Shan
Department of Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong, Hong Kong SAR, China.
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Ther Adv Musculoskelet Dis. 2024 Oct 5;16:1759720X241284869. doi: 10.1177/1759720X241284869. eCollection 2024.
Axial spondyloarthritis (axSpA) is a complex disease characterized by a diverse range of clinical presentations. The primary manifestation is inflammatory lower back pain, often accompanied by other clinical manifestations such as peripheral arthritis, enthesitis, uveitis, psoriasis, and inflammatory bowel disease. However, the presentation of axSpA can vary widely among patients. Despite extensive research, the precise pathogenesis of axSpA remains largely unknown. The lack of complete understanding poses challenges in subgrouping the disease, developing specific treatment approaches, and predicting treatment response. In this review, we will explore the limitations in diagnosing and treating axSpA. In addition, we will examine the current knowledge and potential opportunities provided by various omics and technological advancements in enhancing the diagnosis and personalized treatment of axSpA.
轴性脊柱关节炎(axSpA)是一种复杂的疾病,具有多种临床表现。其主要表现为炎性下背痛,常伴有外周关节炎、附着点炎、葡萄膜炎、银屑病和炎性肠病等其他临床表现。然而,axSpA在患者中的表现差异很大。尽管进行了广泛的研究,但axSpA的确切发病机制在很大程度上仍不清楚。缺乏全面的了解给该疾病的亚组分类、制定特定的治疗方法以及预测治疗反应带来了挑战。在本综述中,我们将探讨axSpA诊断和治疗中的局限性。此外,我们将研究各种组学和技术进步在增强axSpA诊断和个性化治疗方面提供的现有知识和潜在机会。